Nizar Jacques Bahlis

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.

The paper shows that genomic antigen escape mechanisms in multiple myeloma occur during CAR-T/TCE treatment, not pre-existing, and emerge after one year of therapy.

Copy-scAT deconvolutes single-cell chromatin accessibility to infer genetic subclones in cancer, revealing how genetics influence chromatin profiles and subclonal phenotypes.

The paper identifies IgL translocations in multiple myeloma as a marker of poor prognosis, often misclassified as standard risk due to co-occurrence with hyperdiploidy.